Alzheimer's disease (AD), a chronic age-related neurodegenerative disease, currently affects 10% of adults aged 65 and older. While the amyloid precursor protein (APP), especially Swedish mutant APP (APPswe), is recognized as a significant pathogenic protein in AD, its effect on the skeletal system and underlying mechanisms remain poorly understood.

Werner syndrome (WS) is a rare genetic disorder that causes premature aging and serious complications. In the first clinical trial of its kind, researchers from Japan with the company Niagen Bioscience, investigated the effects of nicotinamide riboside (NR), a vitamin B3 derivative, in patients with WS. NR supplementation significantly improved cardiovascular health, reduced skin ulcer area, and slowed kidney function decline—offering promising therapeutic potential for a disease that currently lacks effective treatment.

Scientists at the CNIC have developed an innovative method for analyzing the mechanical function of proteins through controlled cleavage.